← Back to Search

Virus Therapy

EDP-938 for Respiratory Syncytial Virus (RSVP Trial)

Phase 2
Waitlist Available
Research Sponsored by Enanta Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 3, 5, 9 and 14
Awards & highlights

Summary

This trial tested an oral medicine called EDP-938 in adults with RSV-related upper respiratory infections. The goal was to see if it could reduce the severity and duration of the infection. The study included people with stable asthma or COPD.

Eligible Conditions
  • Respiratory Syncytial Virus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 3, 5, 9 and 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 3, 5, 9 and 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Total Symptom Score (TSS) Area Under the Curve (AUC)
Secondary study objectives
Number of Subjects With RSV RNA Viral Load Below Limit of Detection (LOD)
RSV RNA Viral Load Area Under the Curve (AUC)

Side effects data

From 2022 Phase 2 trial • 82 Patients • NCT04196101
5%
Urinary tract infection
5%
Diarrhoea
3%
Blood creatine phosphokinase increased
3%
Alanine aminotransferase increased
3%
Dyspepsia
3%
Anaemia
3%
Hepatic function abnormal
3%
Blood chloride decreased
3%
Blood cholesterol increased
3%
Urine ketone body present
3%
Headache
3%
Blood sodium decreased
3%
Protein total decreased
3%
Haemoptysis
3%
Leukocytosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
EDP-938
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EDP-938Experimental Treatment1 Intervention
Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days
Group II: PlaceboPlacebo Group1 Intervention
Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EDP-938
2021
Completed Phase 2
~420

Find a Location

Who is running the clinical trial?

Enanta PharmaceuticalsLead Sponsor
33 Previous Clinical Trials
2,266 Total Patients Enrolled
PPDIndustry Sponsor
161 Previous Clinical Trials
36,894 Total Patients Enrolled
Enanta Pharmaceuticals, IncLead Sponsor
39 Previous Clinical Trials
2,933 Total Patients Enrolled
~15 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top